Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc acquired 4,102 shares of Cerecor stock in a transaction dated Friday, November 30th. The stock was bought at an average price of $3.50 per share, for a total transaction of $14,357.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Armistice Capital, Llc also recently made the following trade(s):

  • On Monday, December 3rd, Armistice Capital, Llc purchased 19,495 shares of Cerecor stock. The stock was acquired at an average price of $3.50 per share, for a total transaction of $68,232.50.
  • On Monday, November 26th, Armistice Capital, Llc purchased 35,000 shares of Cerecor stock. The stock was acquired at an average price of $3.58 per share, for a total transaction of $125,300.00.
  • On Friday, November 23rd, Armistice Capital, Llc acquired 5,000 shares of Cerecor stock. The shares were purchased at an average cost of $3.64 per share, for a total transaction of $18,200.00.
  • On Wednesday, November 21st, Armistice Capital, Llc acquired 10,000 shares of Cerecor stock. The shares were purchased at an average cost of $3.58 per share, for a total transaction of $35,800.00.
  • On Monday, November 19th, Armistice Capital, Llc purchased 23,800 shares of Cerecor stock. The shares were bought at an average cost of $3.56 per share, for a total transaction of $84,728.00.
  • On Thursday, November 15th, Armistice Capital, Llc acquired 11,218 shares of Cerecor stock. The stock was acquired at an average cost of $3.80 per share, for a total transaction of $42,628.40.
  • On Tuesday, November 13th, Armistice Capital, Llc acquired 15,287 shares of Cerecor stock. The stock was acquired at an average cost of $3.90 per share, for a total transaction of $59,619.30.
  • On Wednesday, October 31st, Armistice Capital, Llc purchased 4,586 shares of Cerecor stock. The shares were bought at an average price of $3.91 per share, with a total value of $17,931.26.
  • On Monday, October 29th, Armistice Capital, Llc purchased 33,292 shares of Cerecor stock. The shares were bought at an average price of $3.94 per share, with a total value of $131,170.48.
  • On Friday, October 26th, Armistice Capital, Llc acquired 55,899 shares of Cerecor stock. The shares were bought at an average price of $3.94 per share, with a total value of $220,242.06.

Shares of CERC stock opened at $3.40 on Friday. The firm has a market capitalization of $139.15 million, a price-to-earnings ratio of 8.10 and a beta of 1.40. The company has a current ratio of 0.74, a quick ratio of 0.70 and a debt-to-equity ratio of 0.74. Cerecor Inc has a 12 month low of $1.42 and a 12 month high of $5.74.

CERC has been the subject of several analyst reports. ValuEngine upgraded Cerecor from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. TheStreet raised shares of Cerecor from a “d” rating to a “c” rating in a research note on Monday, November 12th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Cerecor by 630.4% in the 2nd quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock worth $120,000 after purchasing an additional 23,752 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Cerecor in the third quarter valued at approximately $169,000. Finally, Spark Investment Management LLC bought a new position in shares of Cerecor in the second quarter valued at approximately $288,000. Hedge funds and other institutional investors own 44.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Cerecor Inc (CERC) Director Buys $14,357.00 in Stock” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/insider-buying-cerecor-inc-cerc-director-buys-14357-00-in-stock/2668103.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Recommended Story: Calculate Your Return on Investment (ROI)

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.